Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Analyst Ratings

NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD

7.76  +0.03 (+0.39%)

After market: 8.25 +0.49 (+6.31%)

Buy % Consensus

82

ChartMill assigns a Buy % Consensus number of 82% to LFCR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 10.2. This target is 31.44% above the current price.
LFCR was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LFCR.
In the previous month the buy percentage consensus was at a similar level.
LFCR was analyzed by 9 analysts. More opinions would make the average more meaningful.

Related screens

LFCR Historical Analyst RatingsLFCR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -32 -29 -26 -23 -20 -17 -14 -11 -8 -5 -2 2 4 6 8

Price Target & Forecast

Price Low Median Mean High 7.7610.1010.2010.2010.50 - 30.15% 31.44% 31.44% 35.31%

Related screens

LFCR Current Analyst RatingLFCR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2025-05-21 William Blair Initiate Outperform
2025-01-03 Stephens & Co. Reiterate Equal-Weight -> Equal-Weight
2024-11-22 Craig-Hallum Maintains Buy -> Buy
2024-09-05 Craig-Hallum Initiate Buy
2024-08-28 Barrington Research Downgrade Outperform -> Market Perform
2023-09-01 Barrington Research Maintains Outperform -> Outperform
2023-09-01 Stephens & Co. Maintains Equal-Weight -> Equal-Weight
2023-06-02 Barrington Research Maintains Outperform -> Outperform
2023-05-24 Barrington Research Maintains Outperform -> Outperform
2023-03-21 Barrington Research Maintains Outperform
2023-03-20 Barrington Research Maintains Outperform
2023-03-20 Stephens & Co. Downgrade Overweight -> Equal-Weight
2023-03-17 Stephens & Co. Reiterate Overweight